Does Nicotinamide Riboside Actually Raise NAD+ Levels in Dogs?

Start with what you can actually watch happen in your kitchen. A twelve-year-old, sixty-pound golden retriever mix takes longer to get up off the tile now, maybe four or five seconds where it used to be one. That is not a diagnosis. It is a data point, and data points accumulate into a picture of aging that families and veterinarians build together over months, not in a single dramatic visit.

Nicotinamide riboside, often shortened to NR, is a form of vitamin B3 that the body converts into NAD+, a coenzyme every cell needs to run its basic energy and repair machinery. The question owners bring me is simple: if I give my dog an NR supplement, does it actually raise NAD+ in his body, the way it seems to in people? The honest answer has two layers, and both matter.

What the human evidence actually shows

The clearest data on NR and NAD+ comes from people, not dogs. In a PLOS One pharmacokinetics study, healthy volunteers who took escalating doses of NR up to 1,000 mg twice daily over nine days saw blood NAD+ concentrations rise roughly two-fold on average, with single doses producing dose-dependent increases in the blood NAD+ metabolome. That is a real, measured, repeatable physiological effect in humans. Niacin itself, the vitamin family NR belongs to, is described by the National Institutes of Health as the metabolic precursor of NAD, involved in more than 400 enzyme reactions covering everything from energy transfer to genome maintenance, according to the NIH Office of Dietary Supplements. So the mechanism is not speculative. It is well established biochemistry.

What does not automatically follow is that a dog’s liver, gut, and cellular transport systems handle NR identically to a human’s. Dogs are not small people, and canine pharmacokinetics for NR specifically have not been published with the same rigor as the human trials. That gap is where I get careful with families, and it is where I part ways with marketing copy that quietly borrows the human blood-level data and applies it to a chew.

The dog study that gets cited, and what it did not measure

There is a genuine, peer-reviewed canine trial worth knowing about. A randomized, controlled clinical trial published in Scientific Reports gave senior dogs with mild to moderate cognitive impairment a combination of a senolytic compound and an NAD+ precursor, and found improved owner-assessed cognitive function relative to placebo, according to Nature. That is meaningful, real-world evidence that an NAD+ precursor combination can move an outcome owners actually notice, cognition and activity as reported at home. But read it precisely: the trial measured owner-reported cognitive scores and activity monitors, not a direct before-and-after blood NAD+ assay in the dogs. It supports that the strategy of raising NAD+ availability may help senior canine cognition. It does not, by itself, prove that oral NR raises measurable blood NAD+ in dogs the way the human PK study proved it in people.

I think about aging less as a single verdict and more as information gathered one observation at a time, and that framework applies directly here. One study tells you a plausible mechanism worked at the level of behavior. Another tells you the same class of molecule raises blood NAD+ in a different species. Neither alone answers “does this specific supplement, in my specific dog, raise NAD+ measurably.” Both are useful. Neither is proof standing on its own.

I remember weighing this with a family whose ten-year-old, thirty-eight-pound border collie mix had started sleeping through parts of the afternoon he used to spend supervising the yard. They had already tried a joint supplement with no clear change after six weeks and wanted to know whether adding an NAD+ precursor was worth the cost on top of that. We talked through what “worth it” meant: not a promise of reversed aging, but a reasonable, low-risk addition alongside diet, exercise, and a cognitive screening at his next visit. That conversation, not the supplement bottle, was the actual intervention.

Where quercetin and resveratrol fit, and where they do not

Owners frequently ask about stacking NR with other longevity ingredients, so it is worth being precise about what each one is actually supported to do. Quercetin is a flavonoid with antioxidant properties studied for immune and cellular support. Separately, in laboratory research using a nematode model, quercetin formulations and unformulated quercetin, along with NAC and ascorbic acid, did not affect feeding behavior at the concentrations tested, according to a study indexed at DOI.3390/ph19040525 — a reminder that antioxidant ingredients studied in simple organisms do not automatically translate into a dog-specific NAD+ effect. Resveratrol research shows a similar pattern of nuance: in one in-vitro model, embryonic exposure to a specific resveratrol concentration accelerated developmental stages but shortened adult lifespan, per a study at DOI.1016/j.phymed.2026.158531. Dose and context change outcomes. None of that is a reason to avoid these ingredients; it is a reason not to assume “antioxidant” automatically means “raises NAD+” or “extends lifespan” in a dog.

There is an edge case worth naming, because it changes how I apply all of this in practice. A family came in with a fourteen-year-old, nineteen-pound terrier mix already on three supplements for arthritis and cognition, and wanted to add an NAD+ precursor on top. By day 10 of layering a fourth product, the owner could not tell me which change, if any, was doing what. That is the practical risk with stacking ingredients whose individual dog-specific effects are still being established: you lose the ability to observe anything meaningfully. I generally recommend adding one longevity-focused ingredient at a time and giving it six to eight weeks before judging it, specifically so a family can attach an observation to a cause. If you are watching for gait or movement changes as an early marker, our companion piece on what shorter front-leg steps may tell us about cognitive change in senior dogs walks through one specific sign worth flagging to your vet.

Where I land

NR raising NAD+ is well demonstrated in humans and biochemically plausible in dogs, but the direct canine blood-level proof is not yet published at the same standard. The strongest counterargument, and it is a fair one, is that the Scientific Reports trial already shows a downstream benefit in dogs, so maybe the blood-level mechanism does not need separate proof to matter clinically. I take that seriously. I still land on being precise with families: I will say an NAD+ precursor combination improved owner-assessed cognitive outcomes in a real canine trial, and that a related human study shows the same class of molecule reliably raises blood NAD+. I will not say we have direct dog blood-NAD+ data for NR specifically, because we do not, and overstating it erodes the trust families need when the next, murkier claim comes along.

The next step is not to abandon the ingredient. It is to bring your dog’s specific timeline, weight, and any observable changes to your veterinarian before adding it, so the decision is grounded in your dog rather than in a study population that may not resemble him.